The Get Data Out programme routinely publishes cancer statistics produced by NHS D (previously PHE) in a consistent table, called the Get Data Out (GDO) table. This table collects patients into groups with common characteristics, and then publishes information such as incidence, treatment rates, survival and Routes to Diagnosis for these groups.

This document sets out the definitions of the cohort and groups in the Get Data Out tables for the 2023 release of data on testicular tumours including post-pubertal teratomas, between 2013 and 2020.

Testicular tumours, including post-pubertal teratomas cohort

The cohort of testicular tumours, including post-pubertal teratomas used for Get Data Out is all tumours coded in ICD-10 to C62 and D29.2, male patients only.


D29.2 has been included, as certain testicular tumours now considered to be malignant are coded to this site in ICD-10.

Please note that this cohort may differ from others relating to testicular cancer produced by ONS and NCRAS.

Tumour Type

Tumours were classified as Seminoma, Non-seminoma and Other by ICD-O-2 morphology code as documented in the Appendix.

Cohort and classifications were created with Dr Jonathan Shamash of St Bartholomew’s Hospital, London, Professor Dan Berney of Barts Health NHS Trust and Dr Brian Rous at NCRAS.


Tumours of seminoma and non-seminoma morphologies were split by stage at diagnosis into:

The registration of 2019 tumours were being completed during the COVID-19 pandemic. This led to reduced access to the usual data sources, and despite the registry’s best efforts a noticeable decrease in data quality in some fields. This is most commonly seen in an increase in ‘stage unknown’ tumours, and a corresponding decrease in other stage groups. This should be noted when undertaking time-series analysis on the data.

The vast majority of cases are staged in either the UICC 7 or UICC 8 system, where the recommended staging system changed from UICC 7 to UICC 8 between 2017 and 2018 diagnoses. A very small percentage of cancers (less than 1%, apart from in 2016, when UICC6 accounted for 1.902%), were staged in other systems, as reported in the known limitations page. The following table shows the percentage of cases staged in each of UICC7 and UICC8 over time.


Tumours of seminoma and non-seminoma morphologies diagnosed at stage 1 were further split by patient age at diagnosis. Seminoma tumours were split into the following age groups:

Non-seminoma tumours were split into the following age groups:


Morphology-tumour type look-up for testicular tumours, including post-pubertal teratomas